

Cadila explores international collaborations to improve healthcare

24 June 2019 | News

Cadila Pharma shows its prowess in finished formulations & API at IPHEX 2019



Cadila Pharmaceuticals, a global leader in the Pharmaceutical Industry, participated in IPHEX 2019, to further enhance its scope by opening new avenues. IPHEX hosted by PHARMEXCIL at the Helipad Ground, Gandhinagar on June 10 brought together buyers from more than 130 countries.

Participating in this three-day future-oriented development event of this industry Cadila Pharma, presented its life-science value chain amongst thousands of industry experts, seller, manufacturers and policymakers. Furthermore, the company's primary capabilities were discussed at this platform to encourage business enquires from over 150 buyers from 50 countries.

With a vision to improve business outcomes with collaborative efforts, the exhibition came as a great opportunity for Cadila Pharma, along with those from the farthest corners of India.

Representing an offering of customized solutions for every business need, Mr Mahidhwaj Sisodia, Executive Vice President, International Business, said "The Indian healthcare and pharmaceutical industry is at its pinnacle and the demand for finished formulations and APIs is growing. We had one of the busiest stall in IPHEX and received a stellar review and interest by the countries and attendees coming forth. We would like to thank all the delegates and partners for having shown the confidence in the interactions with our team".

Cadila Pharma's extensive range of finished dosage formulations covers every aspect of human life. We provide affordable innovations that make life better and healthier. Our basket of formulations contains more than 850 products belonging to 45 therapeutic segments and 12 specialties including Anti TB, Cardiovascular, Gastrointestinal, Analgesics, Haematinics, Anti-infectives, Respiratory, Antidiabetics, and Oncology.

Their strength area includes contract research facility; discovering unmet medical needs for generics and new chemical entities; synthesizing and exporting high-quality API and intermediaries; finished formulations for multiple therapies and much more.